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rat model of overactive bladder induced by
partial urethral obstruction: is NRG-1 a new
biomarker of overactive bladder?
Hoon Jang, Dong Seok Han and Seung Mo Yuk*Abstract
Background: To determine whether neuregulin-1(NRG-1) is a potential new biomarker of overactive bladder (OAB)
induced by partial urethral obstruction in a rat model of OAB and to evaluate the urothelium as a therapeutic
target of OAB.
Methods: Female Sprague–Dawley rats were separated into three 20-animal groups: normal, OAB, and
5-hydroxymethyl tolterodine (5-HMT)-treated OAB. In the OAB and OAB + 5-HMT groups, the urethra of each animal
was partially obstructed; the OAB + 5-HMT group received intravenous 5-HMT for 3 weeks. At the conclusion of the
5-HMT dosing, the rats in each group underwent cystometrography, and the bladders were histologically evaluated.
The expression of brain derived-neurotrophic factor (BDNF) and NRG-1 were evaluated in the urothelium.
Results: Compared with the control group, the OAB group showed a markedly increased bladder weight and a
significant decrease in the micturition interval and volume; rats in the OAB + 5-HMT group showed decreased
bladder weights and an improved micturition interval and volume. BDNF and NRG-1 were expressed at significantly
higher levels in the OAB group, and were significantly reduced in the OAB + 5-HMT group compared with the
control group.
Conclusions: The study suggests that NRG-1 is a potential new biomarker of OAB; the urothelium might be a
therapeutic target for OAB treatment.
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Overactive bladder (OAB) is characterized by the presence
of urinary urgency, with or without urge incontinence,
usually accompanied by daytime frequency and nocturia,
in the absence of proven infection or other obvious path-
ology [1]. Urinary urgency, defined as a sudden compel-
ling desire to void that is difficult to defer, is the unique
symptom that must be present in order to establish the
diagnosis of OAB [2]. Multiple questionnaries (e.g., USS
and OABq) are widely used for quantifying and grading
urgency severity [3,4] because the diagnosis of OAB is
currently based on the presence of subjective symptoms.* Correspondence: doctor6@hanmail.net
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reproduction in any medium, provided the orHowever, objective tests to diagnose OAB and assess
therapeutic outcomes are urgently needed.
Until recently, the best way to objectively diagnose OAB
was to measure detrusor overactivity (DO) because DO is
the urodynamic hall mark of OAB. However, urodynamic
test are invasive and can only identify OAB in half of the
patients, as normal individuals often have asymptomatic,
involuntary detrusor contractions [5]. These facts decrease
the usefulness of this test as a tool for diagnosing OAB.
To improve the diagnosis of OAB, recent studies have fo-
cused on the detection and clinical application of OAB
biomarkers. Some studies have indicated that nerve
growth factor (NGF), brain-derived neurotrophic factor
(BDNF), prostaglandins, cytokines, and C-reactive protein
may be suitable biomarkers of OAB [6].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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epidermal growth factor receptor (EGFR) family of recep-
tors [7] and is produced in numerous isoforms by alterna-
tive splicing, allowing it to perform various functions [8,9].
Acetylcholine receptor-induced activity (ARIA), an alter-
native name for type 1 NRG-1, plays a role in synapse de-
velopment, influencing the upregulation of acetylcholine
receptor genes beneath the endplate after mammalian
motor neurons have made synaptic contact with muscle
fibers. In this study, we focused on the changes in NRG-1
in a rat model of OAB and evaluated its potential as an
OAB biomarker.
Methods
Animal groups and treatment protocol
Sixty, 12-week-old female, Sprague–Dawley rats (250–
300 g, Daehan Biolink, Daejeon, Korea) were used. The ex-
perimental protocol was approved by the Animal Ethics
Committee of the University of Chungnam, South Korea
(CNU-00289) and conducted according to the National
Institutes of Health (USA) guidelines. Rats were separated
into three, 20-animal groups: control, OAB, and OAB+ 5-
hydroxymethyl tolterodine (5-HMT). All rats in the OAB
and OAB + 5-HMT groups underwent partial urethral ob-
struction (PUO) and those in the control group underwent
sham operations. Rats in the OAB + 5-HMT group also re-
ceived 0.1 mg/kg of 5-HMT (Pfizer, Sandwich, UK) via the
tail vein (2 times/week) over 3 weeks. These doses corre-
sponded to the doses clinically used in humans [10]. Cysto-
metrography (CMG) was performed on all rats 4 weeks
after PUO.
Partial urethral obstruction (PUO)
PUOs were created as described by Melman et al. [11].
Briefly, the bladder of each anesthetized rat was approached,
and the proximal urethra exposed, through a lower midline
incision. A 3–0 polypropylene suture was used to tie the ur-
ethra with a 24-G angioneedle sheath. After suturing, the
angioneedle sheath was removed, leaving the urethra par-
tially obstructed. In our experiment, two rats in the OAB
group died during the surgeries and one rat in the OAB+ 5-
HMTgroup also died after operation.
Cystometrography (CMG)
The catheter implantation procedures needed for CMG
were completed 4 days before the evaluation. A cuffed
polyethylene tube (PE20, A-M Systems, Carlsberg, WA,
USA), was inserted through an abdominal incision into
the dome of the bladder and held in place with a purse-
string suture. During CMG, the end of tube was con-
nected to a pressure transducer (Powerlab, ADInstrument,
Sydney, Australia) and an infusion pump (Promed-Tech.,
Bellingham, MA, USA) via a 3-way stopcock, to record
intravesical pressure (IVP) and to infuse saline into thebladder. Micturition volumes (MVs) were recorded
using a fluid collector connected to a force displa-
cement transducer (Grass Instruments, Quincy, MA,
USA). Room-temperature saline was continuously in-
fused into the bladder at a rate of 0.5 mL/min. After the
voiding pattern stabilized, the micturition cycles were
recorded. IVP and MV were recorded synchronously
and continuously using a Chart v 5.5.6 for Windows
data acquisition system (AD Instrument) at a sampling
rate of 2000 Hz.
Tissue preparation for analysis
After CMG, all rats were euthanized, and each animal’s
bladder was excised at the level of the proximal urethra and
weighed. For routine histological analyses, the bladders of
some animals in each of group were fixed overnight with
4% paraformaldehye at 4°C. The fixed tissue was sectioned
and stained with hematoxylin and eosin before being evalu-
ated by a pathologist. The bladders from most animals were
dissected free of the urothelium using microscissor and
microforceps. Each sample was stored at −70°C until
needed. The urothelium was used for reverse transcriptase-
polymerase chain reaction (RT-PCR) analyses.
Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from a frozen urothelium
sample by adding 1 mL of TRIzol (Invitrogen, Carlsbad,
CA, USA) to each sample and homogenizing the tissue
in a 5-mL glass tube. The homogenate was transferred
to a 1.0-mL tube and mixed with 0.2 mL of 99% chloro-
form (Sigma-Aldrich, St. Louis, MO, USA). After incu-
bating for 5 min at room temperature, the homogenate
was centrifuged for 10 min (13,200 × g) at room tem-
perature. The supernatant was transferred to a clean
tube and 1 mL of absolute isopropyl alcohol (Sigma-
Aldrich) was added, followed by centrifugation. The
supernatant was discarded, and the cell pellet was mixed
with 0.5 mL of diethylpyrocarnobate (DEPC, Sigma -
Aldrich), and centrifuged for 10 min (13,200 × g) at room
temperature. After the supernatant was discarded, the
pellet was dried at room temperature, dissolved with
DEPC-treated water, and stored at −75°C. Agarose gel
electrophoresis and ethidium bromide staining, followed
by visual examination under ultraviolet light, was used to
assess the quality and integrity of the recovered RNA sam-
ples. cDNA was prepared using a first-standard cDNA
synthesis kit (Enzynomics, Yuseo, Korea), according to the
manufacturer’s protocol. The cDNA was incubated at 50°C
for 50 min, 70°C for 10 min, and finally stored at −20°C.;
the glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
gene was used as reference standard. After an initial
denaturation step at 95°C for 5 min, 35 annealing cycles
(58°C for 30 s), and an extension procedure (72°C for 30 s
and 72°C for 5 min) were performed. PCR products were
Table 1 Changes in body and bladder weights in the
experimental groups
Control OAB OAB + 5-HMT
Body
Weight (g)
228.13 ± 13.601 229.92 ± 10.727 231.65 ± 13.258
Bladder
Weight (mg)
116.53 ± 8.262 212.08 ± 13.883※ 197.43 ± 13.737※※
OAB overactive bladder group; OAB + 5-HMT overactive bladder treated with
5-hydroxymethyl tolterodine group.
※ Significant difference (P < 0.05) compared with the control group.
※※ Significant difference (P < 0.05) compared with OAB group.
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ide, visualized, photographed on an ultraviolet transillumi-
nator, quantified by densitometry, and qualified by Bio-ID
(Vilber Lourmat, Torcy, France).Data analysis
Data were statistically compared between the 3 groups
using one-way analysis of variances (ANOVA), followed
by Scheffe’s multiple comparison post-hoc test. Compar-
isons between 2 groups were performed using Student’s
t-test. Differences were considered statistically significant
when P < 0.05, with results expressed as the mean (SD).Results
Bladder weight and histological examination
Table 1 shows the body and bladder weights for the 3
groups; the mean body weights for the 3 groups were
not significantly different (P = 0.691). However, the mean
weights of the bladders in the OAB group were signifi-
cantly higher than in the control group (P < 0.001); thereFigure 1 Hematoxylin and eosin staining of bladder tissue. The muscu
A. There was no typical difference in the urothelium between the groups.
treated with 5-hydroxymethyl tolterodine group.were also significant weight differences between the
OAB and OAB + 5-HMT bladders (P < 0.001).
In histological examinations, detrusor muscle hyper-
trophy seemed more extensive in the OAB and OAB +
5-HMT groups than in the control group. However,
there was no typical urothelium difference between
groups (Figure 1).In vivo assessment of bladder function
Table 2 describes the micturition intervals (MIs), pressure
differences between the maximal micturition pressure and
the basal pressure (MP-BP), micturition volumes (MVs),
and the micturition times (MTs) during CMG. Figure 2
shows a representative CMG tracing. CMG revealed signifi-
cant decreases in the MIs (P < 0.001) and MVs (P < 0.001)
in the OAB animals compared with the controls. Further-
more, 5-HMT administration had a significant effect on
MIs (P < 0.001) and MVs (P < 0.001), compared with the
OAB group. The mean MT was significantly higher in the
OAB group (P = 0.010) than in the control group. However
there was no statistical difference between the OAB and
OAB+ 5-HMT groups (P = 0.923); significant differences in
MP-BP were not observed among the 3 groups (P = 0.547).Comparison of growth factors in the urothelium
RT-PCR was used to assess the expression of BDNF and
NRG-1 in urothelium of animals from each group (Table 3).
Figure 3 shows the representative intensity differences for
growth factors in the experimental groups. Expression of
BDNF and NRG-1 was significantly higher in the OAB
group than in the control group (P< 0.001). However, thelar layer appears more hypertrophic in image B and C than in image
A, Control group; B, overactive bladder group; C, overactive bladder
Table 2 Results of cystometric analysis of the
experimental animals
Control OAB OAB + 5-
HMT






(Sec) (Mean ± SD)
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Maximal Micturition Pressure




50.79 ± 8.40 48.17 ± 4.99






(ml) (Mean ± SD)





(Sec) (Mean ± SD)
Pressure Difference between




9.47 ± 6.97 4.74 ± 3.74
(cmH2O) (Mean ± SD)
OAB overactive bladder group; OAB + 5-HMT overactive bladder treated with
5-hydroxymethyl tolterodine group.
※ Significant difference (P < 0.05) compared with the control group.
※※ Significant difference (P < 0.05) compared with OAB group.
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OAB+ 5-HMTgroup than in the OAB group (P < 0.001).Discussion
The diagnosis of OAB is symptom-based and involves
assessing the conscious perception of urinary urgency.
Knowing whether an animal is experiencing urgency, even
if pseudoaffective changes in behavior may suggest it, is
impossible. Animals cannot relate their symptoms to inves-
tigators, and consequently, the creation of an animal model
of OAB has not been technically possible. Nevertheless
several animal model of OAB, involving partial bladder out-
let obstruction, spontaneous hypertension, hyperlipidemia,
various neurological insults, and some gene knock-outs,Figure 2 Typical cystometrograms of the experimental groups. Mictur
group compared with the control group. The OAB + 5-HMT group demons
contractions, not observed in the control group, were observed during the
OAB + 5-HMT, overactive bladder treated with 5-hydroxymethyl tolterodinehave been suggested and used to study the mechanisms
and treatment of OAB [12].
In this study, we used a partial bladder outlet obstruction
animal model. This model has advantages in the replication
of many of the structural and physiological bladder changes
seen in human bladder outlet obstruction and is known to
be a reliable model with good etiological validity [12]. The
main findings of the present study were: (1) bladder weights
increased after PUO, but there was a no apparent his-
tological change in urothelial layer; (2) DO, induced by
PUO, was identified by CMG; (3) BDNF and NRG-1 ex-
pression levels were significantly higher in the OAB
group than in the control group and significantly lower
in the OAB + 5-HMT group than in the OAB group.
In this work, detrusor muscle hypertrophy was histolog-
ically observed in the OAB and OAB+ 5-HMTgroups. Al-
though some reports have suggested that detrusor wall
thickeness is a potential marker of OAB [13], other studies
have suggested that detrusor wall thickness is not a diag-
nostic tool for OAB. Nevertheless, detrusor hypertrophy is
associated with detrusor overactivity and it is important
hallmark of reproducing OAB in animal model. Instead of
measuring detrusor wall thickness, we evaluated bladder
weight because the histology of the bladder tissue was in-
consistent among the groups. Based on these results, we
suggest that the increased bladder weight represents de-
trusor muscle hypertrophy because the detrusor muscle
composes most of the bladder wall and 5-HMT is effective
in decreasing detrusor hypertrophy.
DO is a urodynamic observation characterized by invol-
untary contractions during filling phase of cystometry [1].
However, DO is not an essential characteristic of OAB, as
indicated by a 2006 study that found only 64% of diag-
nosed OAB patients, according to the new International
Continence Society (ICS) definition, had urodynamically
demonstrable DO [5]. The study also showed that more
than 30% of DO patients did not have OAB. Nonetheless,ition interval and micturition volume were decreased in the OAB
trated improvements compared with the OAB group. Involuntary
micturition interval in OAB group. OAB, overactive bladder group;
group.
Table 3 Growth factors density comparisons among the
experimental groups
Value Control OAB OAB + 5-HMT
GAPDH 124.94 ± 0.13 125.14 ± 0.49 124.87 ± 0.79
NRG 1 31.73 ± 0.28 50.02 ± 0.67※ 18.52 ± 0.02※※
BDNF 16.53 ± 0.13 41.14 ± 0.21※ 35.91 ± 0.56※※
OAB overactive bladder group; OAB + 5-HMT overactive bladder treated with
5-hydroxymethyl tolterodine group.
※ Significant difference (P < 0.05) compared with the control group.
※※ Significant difference (P < 0.05) compared with OAB group.
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basic OAB research as urinary urgency cannot be ascer-
tained in animal models of OAB [12]. During CMG in the
present study, MIs and MVs were significantly decreased
and involuntary contractions were present during the MIs
in the OAB group. The decreased MIs and MVs were
thought to correspond to the clinical the frequent and in-
voluntary contractions during MI.
Although the exact mechanism of OAB is not com-
pletely understood, OAB may be related to changes in or
dysfunction of the muscarinic receptors of the detrusor
muscle; other mechanisms may also be involved that in-
clude other receptor systems [14,15]. These changes result
in a predisposition towards unstable bladder contractions
or overactivity of the detrusor muscle. Thus, the major
mechanism of anticholinergic drugs, widely used in treat-
ment of OAB, is their antagonism of the effect of acetyl-
choline on muscarinic receptors in the cholinergically
innervated bladder detrusor muscle. The result is a de-
creased number of detrusor smooth muscle contractions
in the bladder and a reduced intensity of urgency symp-
toms [16,17]. In this study, we used 5-HMT, the active
metabolite of fesoterodine, for treating experimental OAB;
fesoterodine is a widely used muscarinic receptor antagon-
ist for treating OAB, in humans [18]. In our study, theFigure 3 The reverse transcription-polymerase chain reaction for the
group; OAB + 5-HMT, overactive bladder treated with 5-hydroxymethyl tolt
control group. ※※ Significant difference (P < 0.05) compared with OAB grobladder weights, MIs and MVs were improved in the
OAB + 5-HMT group, compared with the OAB group,
suggesting that the changes may be due to the anti-
cholinergic effect of 5-HMT.
In this study, we also isolated the urothelium from the
bladder and estimated BDNF expression as a control
marker of NRG-1 for evaluating NRG-1’s potential as an
OAB biomarker. OAB has been suggested to be related
to neurotransmitters and other receptor systems in the
urothelium. Furthermore, these sensor molecules and
malfunctioning of the urothelium may be linked to the
development of OAB [19-22]. The urothelium is increas-
ingly recognized as a responsive structure capable of
detecting physiological and chemical stimuli, and of
releasing several signaling molecules and various trophic
factors after physical or chemical stimulation. Thus,
the functioning of the urothelium is closely related to
the functioning of the nervous system, and control the
urothelium signaling pathway may be a new therapeutic
target for treatment of OAB.
As described in the Introduction, new, noninvasive tests
to diagnose OAB and assess therapeutic outcomes are ur-
gently needed and some studies have focused on the de-
tection and clinical application of OAB biomarkers [23].
In this study, we presumed that elevated bladder pressure,
caused by PUO, stimulated the urothelium, and increased
the release of neuronal molecules, such as BDNF and
NRG-1. These neuronal molecules were also presumed to
activate a signaling pathway for inducing detrusor muscle
hypertrophy and overactivity. The expected result was an
increase in the number of detrusor smooth muscle con-
tractions and an increased intensity of urgency symptoms.
To confirm this hyposthesis, we measured the expression
of BDNF and NRG-1 in isolated urothelium tissues.
In humans, the BDNF protein is encoded by the BDNF
gene [24]. BDNF is a member of the neutrophin familypresence of urothelial growth factors. OAB, overactive bladder
erodine group. ※ Significant difference (P < 0.05) compared with the
up.
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tor. BDNF is the most abundant neurotrophin in the hu-
man body and contributes to the differentiation, survival
and normal function of sensory neurons [25-28]. Many
studies have suggested that BDNF is a biomarker of
OAB because urinary bladder synthesis of BDNF is
strongly increased after chronic bladder inflammation or
spinal cord injury [29-31]. BDNF sequestration improves
bladder function in rats with chronic cystitis [32], and
the BDNF/creatinine ratio is significantly higher in OAB
patients compared to controls [33]. Furthermore, urinary
concentrations of BDNF are higher at baseline than after
administration of botulinum toxin A to the bladder tri-
gone in patients with bladder pain syndrome/interstitial
cystitis [34]. These positive correlations suggest the po-
tential utility of BDNF as a biomarker of OAB.
In humans, NRG-1 protein is encoded by the NRG-1
gene [7,35] and is a member of the epidermal growth
factor (EGF) family known to activate proliferation, dif-
ferentiation, and survival of many tissue types [7,36-38].
Although the function and mechanism of NRG-1 has
not yet been clearly established, at least 6 major types
(having different N termini) of NRG-1 are known [39].
Type I NRG-1 plays a particular role in synapse de-
velopment, influencing the upregulation of acetyl-
choline receptor genes beneath the endplate after
mammalian motor neurons have made synaptic con-
tact with muscle fibers. ErbB4 is highly expressed
during re-epithelialization of urothelium [40], and
antiadrenergic NRG-1/ErbB signaling disappears when
the muscarinic cholinergic receptor is blocked [41].
In addition, antiadrenergic muscarinic cholinergic sig-
naling is diminished in the absence of NRG-1 [42].
Although the molecular mechanism underlying the
cooperation between the NRG-1/ErbB system and the
cholinergic system are still under investigation, NRG-
1 may be related to the recycling and maintenance of
urothelium and may act in a manner similar to a
cholinergic receptor in the urothelium.
In this study, both BDNF and NRG-1 were expressed at
significantly higher levels in the OAB group, compared with
the control group, and were significantly reduced in the
OAB + 5-HMTgroup compared to the OAB group. As a re-
sult, we suggest that the increased expression of NRG-1 in-
duced upregulation of the acetylcholine receptors, including
detrusor muscle hypertrophy and increasing the involuntary
contraction of the detrusor smooth muscle. Furthermore,
NRG-1 expression may be altered by the anti-cholinergic
drug, 5-HMT, which affected not only the muscarinic recep-
tor in the detruosor muscle but also the muscarinic receptor
in the urothelium. Therefore, the urothelium may be a
therapeutic target for treatment of OAB.
We note that our study has some limitations. In this
study, we compared NRG-1 expression in control, OAB,and OAB + 5-HMT groups without investigating the func-
tion and detailed mechanism of NRG-1 action in the
urothelium. Had we assessed the signaling NRG-1 path-
way in the bladder urothelium, better information about
the function and mechanism of NRG-1 could have been
provided, along with additional evidence for its consider-
ation as an OAB biomarker. However, NRG-1 has not
been studied in urological organ or disease models and
our study was designed to investigate the possibility NRG-
1’s role as a potential OAB biomarker. To clarify NRG-1’s
role as a potential OAB biomarker, further investigations
regarding the relationship between NRG-1 and the blad-
der urothelium signaling pathways are needed.
Conclusions
These results suggest that NRG-1 is a potential bio-
marker of OAB in rat OAB models. The results also sug-
gest that the urothelium is a coordinator, rather than a
simple receptor that detecting physical or chemical stim-
uli, and may release several signaling molecules, making
the urothelium signaling pathway a potential therapeutic
target for OAB treatment.
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